Literature DB >> 26355635

Sensitive Multiplexed Quantitative Analysis of Autoantibodies to Cancer Antigens with Chemically S-Cationized Full-Length and Water-Soluble Denatured Proteins.

Junichiro Futami1, Hidenori Nonomura1, Momoko Kido1, Naomi Niidoi1, Nao Fujieda2,3, Akihiro Hosoi2,3, Kana Fujita1, Komako Mandai1, Yuki Atago1, Rie Kinoshita1, Tomoko Honjo1, Hirokazu Matsushita3, Akiko Uenaka4, Eiichi Nakayama4, Kazuhiro Kakimi3.   

Abstract

Humoral immune responses against tumor-associated antigens (TAAs) or cancer/testis antigens (CTAs) aberrantly expressed in tumor cells are frequently observed in cancer patients. Recent clinical studies have elucidated that anticancer immune responses with increased levels of anti-TAA/CTA antibodies improve cancer survival rates. Thus, these antibody levels are promising biomarkers for diagnosing the efficiency of cancer immunotherapy. Full-length antigens are favored for detecting anti-TAA/CTA antibodies because candidate antigen proteins contain multiple epitopes throughout their structures. In this study, we developed a methodology to prepare purified water-soluble and full-length antigens by using cysteine sulfhydryl group cationization (S-cationization) chemistry. S-Cationized antigens can be prepared from bacterial inclusion bodies, and they exhibit improved protein solubility but preserved antigenicity. Anti-TAA/CTA antibodies detected in cancer patients appeared to recognize linear epitopes, as well as conformational epitopes, and because the frequency of cysteine side-residues on the epitope-paratope interface was low, any adverse effects of S-cationization were virtually negligible for antibody binding. Furthermore, S-cationized antigen-immobilized Luminex beads could be successfully used in highly sensitive quantitative-multiplexed assays. Indeed, patients with a more broadly induced serum anti-TAA/CTA antibody level showed improved progression-free survival after immunotherapy. The comprehensive anti-TAA/CTA assay system, which uses S-cationized full-length and water-soluble recombinant antigens, may be a useful diagnostic tool for assessing the efficiency of cancer immunotherapy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26355635     DOI: 10.1021/acs.bioconjchem.5b00328

Source DB:  PubMed          Journal:  Bioconjug Chem        ISSN: 1043-1802            Impact factor:   4.774


  5 in total

1.  Engineering Cancer/Testis Antigens With Reversible S-Cationization to Evaluate Antigen Spreading.

Authors:  Ai Miyamoto; Tomoko Honjo; Mirei Masui; Rie Kinoshita; Hiromi Kumon; Kazuhiro Kakimi; Junichiro Futami
Journal:  Front Oncol       Date:  2022-05-04       Impact factor: 5.738

2.  Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy.

Authors:  H Kumon; Y Ariyoshi; K Sasaki; T Sadahira; M Araki; S Ebara; H Yanai; M Watanabe; Y Nasu
Journal:  Cancer Gene Ther       Date:  2016-10-21       Impact factor: 5.987

3.  Inducing multiple antibodies to treat squamous cell esophageal carcinoma.

Authors:  Isamu Hoshino; Yoshihiro Nabeya; Nobuhiro Takiguchi; Hisashi Gunji; Fumitaka Ishige; Yosuke Iwatate; Akiko Kuwajima; Fumiaki Shiratori; Rei Okada; Hideaki Shimada
Journal:  BMC Cancer       Date:  2020-10-17       Impact factor: 4.430

4.  Evaluation of irreversible protein thermal inactivation caused by breakage of disulphide bonds using methanethiosulphonate.

Authors:  Junichiro Futami; Ai Miyamoto; Atsushi Hagimoto; Shigeyuki Suzuki; Midori Futami; Hiroko Tada
Journal:  Sci Rep       Date:  2017-09-29       Impact factor: 4.379

5.  Autoimmunity to the Follicle-Stimulating Hormone Receptor (FSHR) and Luteinizing Hormone Receptor (LHR) in Polycystic Ovarian Syndrome.

Authors:  Hanna A Schniewind; Lisa-Marie Sattler; Christoph W Haudum; Julia Münzker; Waldemar B Minich; Barbara Obermayer-Pietsch; Lutz Schomburg
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.